Is Tramadol Habit Forming? Risks and Withdrawal

Tramadol is habit-forming. It was marketed for decades as a safer alternative to stronger opioids, and that reputation led many prescribers and patients to underestimate its addictive potential. But tramadol activates the same brain receptors that make other opioids addictive, and stopping it after regular use can produce a withdrawal syndrome that, in some ways, is more complicated than withdrawal from other painkillers. The story of tramadol’s risks is really about how its unusual chemistry creates a false sense of security.

How Tramadol Works and Why That Matters for Dependence

Tramadol is not a typical opioid. It works through two distinct pathways at once. One component binds to the mu opioid receptor, the same target that morphine, oxycodone, and heroin hit. The other component blocks the reuptake of serotonin and norepinephrine, two brain chemicals involved in mood, alertness, and pain modulation.¹ This dual mechanism is what makes tramadol effective for pain but also what makes its dependence profile unusually tricky.

When you take tramadol, your liver converts part of it into a metabolite called O-desmethyl-tramadol (often abbreviated M1), which is actually a much stronger opioid than the parent drug. The M1 metabolite does the heavy lifting at the mu opioid receptor.² This is a key detail, because how much M1 your body produces depends on your genetics, which means tramadol’s addictive potential varies from person to person in ways that are hard to predict at the time of prescribing.

Because tramadol’s opioid effect is somewhat milder than drugs like oxycodone, it earned a reputation as the “gentle” opioid. Researchers have noted that it produces fewer side effects than classic opioids at standard doses.² That characterization is not wrong exactly, but it created a widespread misunderstanding that “milder” meant “not addictive.” It is addictive. The opioid component, however modest compared to morphine, still triggers the reward circuits in the brain that drive dependence with repeated use.

Who Is Most at Risk

Not everyone who takes a short course of tramadol for a pulled muscle or post-surgical pain will develop a problem. But certain factors raise the odds considerably. A Swedish survey of spontaneously reported tramadol dependence cases found that about 30% of those who developed dependence had a documented history of substance abuse, and roughly 40% had past or current use of another drug of abuse.³ A prior relationship with addictive substances is the single clearest red flag.

But it is not the only one. A systematic review of case reports describing psychological side effects of tramadol identified several risk factors: older age, pre-existing psychiatric conditions, use of multiple drugs simultaneously, and prolonged tramadol use. Elderly people and those with psychiatric histories were particularly vulnerable.⁴ Depression appears to play a role too. In a study of adolescents and young adults in treatment for problematic substance use, those who misused tramadol and had a history of depression were significantly less likely to complete their treatment program.⁵

Duration matters as well. A prescription lasting a week or two for acute pain carries far less risk than months of daily use for chronic pain. The brain adapts to the drug’s presence over time, and that adaptation is the physiological basis for both tolerance (needing more to get the same effect) and dependence (feeling bad when you stop).

Withdrawal Is More Complicated Than With Other Opioids

This is where tramadol’s dual mechanism becomes a real problem. If you stop taking it abruptly after weeks or months of regular use, you can experience two overlapping sets of withdrawal symptoms. One set looks like typical opioid withdrawal: muscle aches, sweating, nausea, diarrhea, restlessness, and insomnia. Anyone who has seen or experienced opioid withdrawal will recognize these.

The second set is atypical and stems from tramadol’s effect on serotonin and norepinephrine. These symptoms can include severe anxiety, panic attacks, confusion, hallucinations, and in rare cases, psychosis. A case report documented a patient who developed frank psychosis during tramadol withdrawal, with symptoms that resolved within days once the withdrawal was properly managed.⁶ These atypical symptoms are not something most patients or even some doctors expect, because tramadol is often thought of as “just” a mild opioid. The serotonin and norepinephrine component means that stopping tramadol can feel more like discontinuing an antidepressant and an opioid at the same time.

This hybrid withdrawal profile makes tapering especially important. Quitting cold turkey is riskier with tramadol than with many other opioids, not because the opioid withdrawal is necessarily worse, but because the additional neurochemical disruption adds layers of discomfort and unpredictability. A gradual dose reduction, supervised by a doctor, is the standard approach for anyone who has been taking tramadol regularly for more than a few weeks.

The Genetic Factor Most People Don’t Know About

Your body’s ability to convert tramadol into its active metabolite M1 depends on a liver enzyme called CYP2D6, and people carry different versions of the gene that codes for it. This creates a spectrum. Some people are ultrarapid metabolizers who convert tramadol to M1 very quickly, flooding their system with a stronger opioid than intended. Others are poor metabolizers who barely produce M1 at all, meaning the drug gives them less pain relief and less opioid-like reward.

Research has confirmed that intermediate metabolizers, for instance, show higher tramadol blood levels and lower clearance compared to normal and ultrarapid metabolizers.⁷ The practical consequence is that two people taking the same dose can have very different experiences. An ultrarapid metabolizer may feel a strong euphoric opioid effect, which increases addiction risk. A poor metabolizer may feel little relief and be tempted to take more than prescribed. Neither scenario is ideal, and pharmacogenomic testing to determine CYP2D6 status before prescribing tramadol is not yet routine in most clinical settings.

Seizures and Serotonin Syndrome

Two serious adverse effects stand apart from tramadol’s addictive potential but are closely related to how it is used and misused: seizures and serotonin syndrome.

Tramadol lowers the seizure threshold, meaning it makes seizures more likely. This risk exists even at therapeutic doses but climbs sharply with overdose or misuse. In a study of patients hospitalized for tramadol intoxication, seizures occurred in about 58% of cases. The risk increased nearly fourfold in patients who had a prior history of seizures. Higher doses correlated with more severe presentations, including repeated seizure episodes.⁸ Both seizures and serotonin syndrome can develop during tramadol monotherapy, but they are much more likely during misuse, overdose, or when the drug is combined with antidepressants.⁹

Serotonin syndrome is a potentially life-threatening reaction caused by too much serotonin activity in the brain. Because tramadol blocks serotonin reuptake, combining it with other serotonin-boosting drugs like SSRIs or SNRIs (commonly prescribed antidepressants) can push serotonin levels dangerously high. Symptoms include agitation, rapid heartbeat, muscle twitching, fever, and in severe cases, organ failure. The incidence with this combination is relatively low and most cases are mild to moderate, but serotonin syndrome is more easily prevented than treated.¹⁰ If you take an antidepressant, make sure your prescriber knows before starting tramadol.

How Tramadol Compares to Other Opioids for Harm

One argument that has historically supported tramadol prescribing is that it causes fewer serious harms than stronger opioids like hydrocodone or oxycodone. There is some evidence behind this. A large comparative study of people with chronic non-cancer pain found that low-dose tramadol was not associated with a higher risk of opioid overdose compared to low-dose hydrocodone. It was actually associated with lower rates of accidents, self-inflicted injuries, and violence-related injuries.¹¹

That is a meaningful finding, but context matters. “Lower risk than hydrocodone” is not the same as “low risk.” Tramadol still carries the potential for dependence, withdrawal, seizures, and serotonin-related complications that hydrocodone does not. The comparative data supports using tramadol as a first-line option when an opioid is truly needed, rather than jumping straight to a stronger drug. It does not support treating tramadol as a non-issue.

The Overdose Complication With Naloxone

In a standard opioid overdose, the antidote naloxone (the drug in Narcan) reverses respiratory depression and can be lifesaving. Tramadol overdoses are less straightforward. In animal studies, naloxone successfully reversed tramadol-induced respiratory depression but significantly increased seizure activity and prolonged the time seizures lasted.¹²

This creates a clinical dilemma in emergency settings. If someone has overdosed on tramadol and is not breathing well, naloxone can restore breathing but may trigger or worsen seizures. Emergency physicians have to weigh these competing risks. For bystanders, naloxone is still the appropriate response if someone is not breathing after a suspected opioid overdose of any kind, because respiratory arrest is the immediate threat to life. But this quirk of tramadol overdose is another reminder that the drug behaves differently from what most people expect of an opioid.

Tramadol During Pregnancy and Neonatal Withdrawal

When a pregnant person takes tramadol regularly, the baby can develop physical dependence in the womb and experience withdrawal symptoms after birth. Case reports have documented neonatal withdrawal starting within 36 to 48 hours of delivery, with symptoms including jitteriness, involuntary muscle movements, and irritability.¹³ ¹⁴ In one case involving long-term, high-dose maternal use, the infant’s withdrawal was prolonged and required treatment with clonidine.

This is not unique to tramadol. Any opioid used regularly during pregnancy can cause neonatal abstinence syndrome. But because tramadol is often perceived as milder, some prescribers and patients may not fully appreciate this risk. If you are pregnant or planning to become pregnant and currently take tramadol, that conversation with your doctor should happen sooner rather than later.

How Scheduling Has Changed Tramadol’s Availability

For years, tramadol was not classified as a controlled substance in the United States. It was treated essentially like any prescription medication, with no special restrictions on refills or monitoring. That changed in 2014 when the DEA placed it in Schedule IV, a category that includes drugs considered to have a low potential for abuse relative to Schedule III substances. Individual states had already begun scheduling it earlier, and the effects of those state-level changes offer a useful natural experiment.

In Arkansas and Kentucky, which scheduled tramadol before the federal change, poison center exposures to tramadol dropped after scheduling, declining by about 5% to 31% annually. Meanwhile, comparison states that had not yet scheduled the drug saw continued increases of 14% to 23%.¹⁵ Scheduling appears to have reduced misuse where it was implemented.

But there is a catch. Research on opioid scheduling more broadly has found that tightening restrictions on one opioid tends to reduce its use while increasing prescriptions of close competitors that remain less restricted, resulting in no overall reduction in total opioid prescriptions.¹⁶ In other words, supply restrictions on a single drug can push the problem sideways rather than solving it. This pattern has played out repeatedly in opioid policy and is a reminder that scheduling alone is not a complete strategy.

Tramadol’s Growing Role Outside Prescription Medicine

In parts of North Africa and West Africa, tramadol has become a widely consumed recreational drug, often obtained as falsified or counterfeit tablets sold outside any medical system. The Egyptian government has requested that the United Nations Commission on Narcotic Drugs place tramadol under international control, a step that goes beyond its current national-level scheduling in most countries. The non-medical use of tramadol in these regions has been driven in part by its relatively easy availability and the perception, shared globally, that it is safer than other opioids.

At the same time, tramadol has been prescribed off-label for conditions unrelated to pain, including premature ejaculation. Its serotonin effects are thought to be the relevant mechanism for that use. However, reviews of this practice have noted that the evidence supporting tramadol for premature ejaculation is not strong, and the risk of dependence makes it a questionable long-term choice for a non-life-threatening condition.¹⁷ Any off-label use that involves repeated dosing amplifies the dependence risk, because the brain’s adaptation to tramadol does not care why you are taking it.

Prescribing Trends and What They Reveal

In the UK, a large retrospective study of primary care patients with non-cancer pain found that tramadol prescriptions rose between 2006 and 2012, then leveled off through 2017.¹⁸ That plateau coincided with growing awareness of tramadol’s dependence potential and tighter prescribing guidelines. The trajectory mirrors what has happened in several countries: an initial period of enthusiastic prescribing driven by the belief that tramadol was low-risk, followed by a correction as real-world evidence accumulated.

The broader lesson from tramadol’s history is that “milder than morphine” was never the same as “safe.” Every opioid that acts on the mu receptor carries dependence risk. Tramadol’s unique chemistry adds complications — atypical withdrawal, seizure risk, serotonin interactions — that other opioids do not share. If you are prescribed tramadol, it can be an appropriate medication for the right situation, at the right dose, for the right duration. The problems begin when any of those conditions are relaxed, and the drug’s gentle reputation has historically made all three easier to relax than they should be.